EUROPEAN DISPARITIES IN ACCESS TO ^{177}Lu-PSMA RADIOLIGAND THERAPY FOR mCRPC

AUTHORS: Thais Rocha, Elisa Cannarozzo, Catherine Bouvier, Laura Ravasi, Alice Viana
AFFILIATION: The Oncidium foundation *The authors declare that they have no conflicts of interest.*

european cancer SUMMIT 2026

BACKGROUND

- ^{177}Lu-PSMA RLT is recognised by EAU and ESMO as a standard of care for advanced prostate cancer (mCRPC).
- Yet across Europe, regulatory authorisation does not ensure reimbursement or patient access.
- In mCRPC, where prognosis is measured in months, delays in access are clinically indistinguishable from denial.

THREE BARRIERS. ONE FRAMEWORK.

AVAILABILITY
- EMA approval ≠ patient access
- National reimbursement is fragmented
- Radioisotope supply chain gaps

AWARENESS
- Patients are often unaware that RLT exists
- Referring oncologists may not consider RLT
- Nuclear medicine stigma persists

ABILITY
- Specialised NM teams are required
- Investment in radiation safety infrastructure
- Training programmes are often insufficient

FROM EMA APPROVAL TO PATIENT ACCESS

Regulatory approval does not ensure national reimbursement.

49 COUNTRIES
European countries reviewed
100%

EMA MARKETING AUTHORISATION
9 December 2022
27 EU + 3 EEA countries

41 COUNTRIES
Clinical use available
84%

8 countries (16%)
No access / no RLT

21 COUNTRIES
Full public reimbursement
43%

20 countries (41%)
Limited or no reimbursement

WHAT THIS MEANS FOR PATIENTS

~21,000 eligible patients annually across Europe



~6,000 patients with full access

~15,000 patients with limited or no access

THE WEST-EAST DIVIDE

WESTERN EUROPE
(18 countries)



58%
FULL REIMBURSEMENT

42% LIMITED / NO REIMBURSEMENT

EASTERN EUROPE
(25 countries)



28%
FULL REIMBURSEMENT

76% LIMITED / NO REIMBURSEMENT

SAME EMA APPROVAL. DIFFERENT REALITIES.

FRANCE

FULL ACCESS

Specialised NM teams in place. 43 hospitals fully reimbursed

UNITED KINGDOM

NOT NHS FUNDED

Clinicians are aware but cannot prescribe with routine NHS funding.

SPAIN

UNDER REVIEW

HTA evaluation ongoing; routine use pending.

THE GAP CANNOT WAIT.

Oncidium fills critical gaps today, but durable change requires systemic commitment from all stakeholders.

COUNTRIES & REGULATORY BODIES
- Harmonise reimbursement
- Accelerate HTA processes
- Ensure equitable access to EMA-approved therapies

HEALTHCARE PROFESSIONALS
- Refer eligible patients early
- Build multidisciplinary RLT pathways
- Advocate for training and infrastructure expansion

INSTITUTIONS
- Invest in nuclear medicine capacity
- Provide dedicated education
- Partner actively with patient organizations

Together, we can close the gap in RLT Access accross Europe.

ONCIDIUMFOUNDATION.ORG